After a few decades of speculation and proof of concept, the biopharmaceutical industry has fully embraced the advantages of single-use technologies throughout all phases of drug production1. In particular, as industry interest shifts to continuous bioprocessing versus traditional batch methods, the flexibility of single-use technologies has once again emerged as an asset to industry advancement. Whether using a batch or continuous process, biopharmaceutical developers want to make high quality products in a cost- and time-efficient manner. The ability to translate laboratory-scale processes to commercial, cGMP-compliant production is key to achieving this aim, and the best way of doing this is to use single-use technologies that are designed with scaleup in mind.